Table 2 Laboratory data of pSLE patients (N = 146)
Clinical features | CMV positive group (N=109) | CMV negative group (N=37) | OR (95% CI) | P value |
|---|---|---|---|---|
Leukopenia (%) | 36 (33) | 11 (29.7) | 1.17 (0.52;2.62) | 0.711 |
Lymphocytopenia (%) | 22 (20.2) | 5 (13.5) | 1.62 (0.57;4.64) | 0.367 |
Anemia (%) | 69 (63.3) | 12 (32.4) | 3.59 (1.63;7.93) | 0.001 |
Thrombocytopenia (%) | 17 (15.6) | 6 (16.2) | 0.96 (0.35;2.64) | 0.929 |
ALB level<35 g/L(%) | 56 (51.4) | 9 (24.3) | 3.29 (1.42;7.612) | 0.004 |
Elevated ALT (%) | 31 (28.4) | 2 (5.4) | 6.96 (1.58;30.69) | 0.004 |
Elevated AST (%) | 33/104 (31.7) | 5/36 (13.9) | 2.88 (1.03;8.08) | 0.038 |
24h urinary protein ≥ 0.5g (%) | 53/96 (55.2) | 12/31 (38.7) | 1.95 (0.85;4.46) | 0.11 |
Low C3 level (%) | 89 (81.7) | 12 (32.4) | 9.27 (3.99;21.52) | <0.001 |
Low C4 level (%) | 88 (80.7) | 11 (29.7) | 9.91 (4.23;23.19) | <0.001 |
Coomb's positivity (%) | 55/84 (65.5) | 14/32 (43.8) | 2.44 (1.06;5.6) | 0.033 |
ANA positivity (%) | 107 (98.2) | 35 (94.6) | 3.06 (0.42;22.52) | 0.266 |
Anti-dsDNA positivity (%) | 90 (82.6) | 15 (40.5) | 6.95 (3.05;15.81) | <0.001 |
Anti-Sm positivity (%) | 34/106 (32.1) | 6 (16.2) | 2.44 (0.93;6.4) | 0.064 |
Anti-RNP positivity (%) | 41/106 (38.7) | 10 (27) | 1.7 (0.75;3.88) | 0.203 |
Anti-rRNP positivity (%) | 37/103 (35.9) | 7 (18.9) | 2.4 (0.96;6) | 0.056 |
Anti-SSA positivity (%) | 46/106 (43.4) | 15 (40.5) | 1.12 (0.53;2.4) | 0.762 |
Anti-SSB positivity (%) | 8/106 (7.5) | 4 (10.8) | 0.67 (0.19;2.38) | 0.508 |
Anti-Ro52 positivity (%) | 15/44 (34.1) | 9/23 (39.1) | 0.81 (0.28;2.29) | 0.683 |
Anti-histone positivity (%) | 29/50 (58) | 5/24 (20.8) | 5.25 (1.69;16.31) | 0.003 |
Anti-nucleosome positivity (%) | 33/50 (66) | 6/25 (24) | 6.15 (2.07;18.26) | <0.001 |
Anticardiolipin (%) | 18/100 (18) | 7/35 (20) | 0.88 (0.33;2.32) | 0.793 |
β2GP1(%) | 17/103 (16.5) | 4/36 (11.1) | 1.58 (0.5;5.06) | 0.234 |
Lupus anticoagulant (%) | 20/103 (19.4) | 12/35 (34.3) | 0.46 (0.2;1.08) | 0.072 |